The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Tilton John since 2017.
This trader's CIK number is 1704251.
At the time of last reporting, Tilton John was the Chief Commercial Officer of Biohaven Pharmaceutical Holding Co Ltd.. (stock ticker symbol BHVN).
Also see all insider trading activities at Biohaven Pharmaceutical Holding Co Ltd..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | BHVN | 0 | $0 | 0 | $0 | 2,125 | $0 |
| 2021 | BHVN | 0 | $0 | 0 | $0 | 2,500 | $0 |
| 2020 | BHVN | 0 | $0 | 52,000 | $3,538,548 | 53,250 | $483,079 |
| 2019 | BHVN | 0 | $0 | 20,500 | $896,635 | 21,750 | $190,443 |
| 2017 | BHVN | 0 | $0 | 30,000 | $880,950 | 30,000 | $278,700 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-01-06 | BHVN | Option Ex | 1,250 | .00 | 0 |
| 2022-01-07 | BHVN | Option Ex | 875 | .00 | 0 |
| 2021-11-25 | BHVN | Option Ex | 1,250 | .00 | 0 |
| 2021-01-06 | BHVN | Option Ex | 1,250 | .00 | 0 |
| 2020-11-25 | BHVN | Option Ex | 1,250 | .00 | 0 |
| 2020-06-10 | BHVN | Sale | 52,000 | 68.05 | 3,538,548 |
| 2020-06-10 | BHVN | Option Ex | 52,000 | 9.29 | 483,079 |
| 2019-12-18 | BHVN | Option Ex | 1,250 | .00 | 0 |
| 2019-03-12 | BHVN | Sale | 10,000 | 50.11 | 501,100 |
| 2019-03-12 | BHVN | Option Ex | 10,000 | 9.29 | 92,899 |
| 2019-01-10 | BHVN | Option Ex | 10,500 | 9.29 | 97,544 |
| 2019-01-10 | BHVN | Sale | 10,500 | 37.67 | 395,535 |
| 2017-11-01 | BHVN | Option Ex | 30,000 | 9.29 | 278,700 |
| 2017-11-01 | BHVN | Sale | 30,000 | 29.36 | 880,950 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Tilton John (Chief Commercial Officer of Biohaven Pharmaceutical Holding Co Ltd. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.